← Eichor
Study identifier: NCT06557057 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk

Condition: HER2-Positive Breast Carcinoma  ·  Sponsor: Mayo Clinic

PhaseN/A
Planned participants66
Who can joinFemale, N/A to no upper limit
Healthy volunteersYes

About this study

This study assesses the effect of hormone directed treatment for breast cancer on glucose metabolism.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trials Referral Office  ·  855-776-0015  ·  mayocliniccancerstudies@mayo.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Mayo Clinic in RochesterRochester, Minnesota, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06557057